IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.
When I first started practicing law, I worked on a wide range of technologies in district court proceedings. I then spent a decade working for the government doing appellate work. Since coming.
The Patent Trial and Appeal Board issued a decision on February 28 awarding priority of invention of foundational CRISPR gene editing patents to the Broad Institute, Massachusetts.